Dominik A. Heim
Distinguished in Chromosome 6 Uniparental Disomy

Dominik A. Heim

Basel, BS, CH 
Distinguished in Chromosome 6 Uniparental Disomy
Basel, BS, CH 
OverviewLocationsClinical Research

Overview

Dominik Heim practices in Basel, Switzerland. Mr. Heim is rated as a Distinguished expert by MediFind in the treatment of Chromosome 6 Uniparental Disomy. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Graft Versus Host Disease (GvHD), Chromosome 6 Uniparental Disomy, Bone Marrow Transplant, and Bone Graft.

His clinical research consists of co-authoring 120 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Chromosome 6 Uniparental Disomy.

Gender
Male

Locations

Basel, BS, Switzerland
Other Locations
Bern, BE, Switzerland
Thun, BE, Switzerland
Hohmad, BE, Switzerland
Schlieren / Spital, ZH, Switzerland
Frutigen, BE, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. A Multicenter, Open-label, Phase II Trial
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. A Multicenter, Open-label, Phase II Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 27, 2025
Intervention Type: Drug
Study Drugs: Ibrutinib, Venetoclax
Study Phase: Phase 2
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drugs: Peginterferon ?2b, Nilotinib
Study Phase: Phase 3
Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission
Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission
Enrollment Status: Terminated
Publish Date: October 14, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 3
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Enrollment Status: Terminated
Publish Date: January 30, 2020
Intervention Type: Biological
Study Phase: Phase 3
View 3 Less Clinical Trials

120 Total Publications

Successful treatment with Tislelizumab and Zanubrutinib in a patient with relapsed/refractory, CD19/CD20 negative Richter's transformed CLL.
Successful treatment with Tislelizumab and Zanubrutinib in a patient with relapsed/refractory, CD19/CD20 negative Richter's transformed CLL.
Journal: Bone marrow transplantation
Published: August 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Heim's expertise for a condition
ConditionClose
      View All 21 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile